Amyloidosis is characterised by the extracellular deposition of abnormal protein fibrils. Recent advances in the study of amyloidosis have been based on the chemical analysis of these protein fibrils.1,2 This has also led to a more rational classification of the condition (Fig 1) . Further discussion of localised forms of amyloidosis is outside the scope of this article, which will be confined to systemic amyloidosis. Systemic amyloidosis may be either inherited or acquired. The neuropathic forms, which show an autosomal dominant inheritance, predominantly affect peripheral nerves, but may involve also the heart, kidneys and other tissues. The protein fibrils are derived from circulating prealbumin, which has an inherited abnormality in the amino acid sequence in some kindreds. 3 The most studied form of inherited non -neuropathic amyloidosis is familial Mediterranean fever (FMF). This autosomal recessive disorder is confined to populations originating on the southern and eastern coasts of the Mediterranean Sea. It is characterised by recurrent acute inflammatory attacks of various types (abdominal pain, polyserositis, arthritis, skin rashes) and the gradual deposition of amyloid protein, most notably in the kidneys. The amyloid fibrils in FMF are derived from a circulating acute phase reactant known as serum amyloid A (SAA) protein. Serum amyloid A is also the major precursor protein of acquired reactive systemic amyloidosis (AA amyloid). This may occur as a complication of chronic inflammatory diseases such as rheumatoid arthritis or chronic infection, and was previously classified as secondary amyloidosis. The other main type of systemic amyloidosis is AL amyloid, which is derived largely from the variable regions of immunoglobulin light chains, secreted by a clone of plasma cells. This clone may give rise to overt myeloma with features such as lytic lesions in bone but may also present solely as amyloidosis. Such cases were previously classified as primary amyloidosis. Amyloidosis is an uncommon condition, with a wide variety of clinical presentations, and for this reason the diagnosis may be overlooked. Three cases presented to a general medical ward within a three -month period. We describe these cases to illustrate the diverse features of the disorder.
CASE I
A 62-year-old lady presented with swollen salivary glands and mild cardiac failure. She also complained of dvsrhacia. loss of hair. eDisodes of sDontaneous bruising around the eyes, and aching muscles. She had been well until one year previously when she had complained of aching leg and back muscles on exertion and had had an operation for spinal stenosis, without improvement in her symptoms. On examination, the submandibular glands were enlarged and had a firm rubbery consistency, the tongue was grossly enlarged and showed indentations made by her teeth (Fig 2) The treatment of AL amyloidosis is unsatisfactory. The most logical approach is to suppress light chain production using regimes such as melphalan and prednisone or cyclophosphamide which are of use for multiple myeloma. A prospective trial of melphalan and prednisone versus placebo showed that the nephrotic syndrome improved in a few patients but survival was not significantly changed.12 Colchicine is effective in preventing amyloidosis in familial Mediterranean fever.13 However, the survival of patients with AL amyloidosis is marginally worse when treated with colchicine as compared to melphalan and prednisone.14 Melphalan and prednisolone were given in Cases 1 and 2 and cyclophosphamide in Case 3. In the first case, amyloidosis progressed despite treatment. In Case 2 the patient died before any response to treatment could have been expected. In Case 3 the patient has remained relatively well following the course of cyclophosphamide, but it is not possible to know whether this can be attributed to the drug.
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